

## ASX Release

### **Anatara Appendix 4C**

MELBOURNE, 29<sup>th</sup> July 2020: Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 30<sup>th</sup> June 2020. The Company's cash plus term deposits at the end of the quarter stood at \$2.7m (31<sup>st</sup> March 2020: \$3.3m). On 30<sup>th</sup> June 2020, the Company had cash at bank of \$1,182,367 and \$1,500,000 in term deposits.

Expenditure during the quarter was lower than forecast and 29% lower than the prior quarter due to the delay in initiation of the GaRP clinical trial. Covid-19 cash preservation initiatives drove quarterly reductions in Staff costs and Administration and Corporate costs of 12% and 27% respectively. For the full year, costs were 15% lower driven by cost containment initiatives which reduced Administration and Corporate costs by 38%.

Aggregate amount of payments to related parties and their associates during the quarter was \$86,000 which includes director's fees and superannuation.

Forecast expenditure for the September 2020 quarter is anticipated to increase as activities for clinical development of the Company's Gastrointestinal Reprogramming (GaRP) over-the-counter (OTC) medicine advance.

Anatara made three announcements during the quarter: (1) partnering update; (2) cancelled options.

While focussing financial resources on development of GaRP, Anatara has been evaluating development, in collaboration with third parties, additional dosage forms for piglets and to utilise Anatara's intellectual property in other species including in-feed formulations for piglets, formulations for aquaculture and formulations for poultry. New formulations are ready for in-feed trials for piglets and trials for poultry.

CEO Steve Lydeamore commented, "Anatara is close to finalising discussions with third parties to progress challenge trials of Anatara's animal health assets to address barriers to partnering. We will continue to provide updates to the market as these activities progress. Anatara anticipates initiation of a GaRP clinical trial in the 4<sup>th</sup> quarter of calendar 2020."



## Anatara's Gastrointestinal ReProgramming (GaRP) OTC medicine

Anatara's GaRP over-the-counter medicine is being developed to specifically target two human gastrointestinal disorders, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). IBS is the most common GI condition affecting approximately 11% of the global population<sup>1</sup> while IBD affects an estimated five million people globally.<sup>2</sup>

GaRP is a single product with multiple benefits, aimed at effectively managing many of the major symptoms experienced by IBS and IBD patients. GaRP has been designed as an everyday option for IBS patients to 1) manage ongoing chronic symptoms and 2) minimise episodic flare ups. The product works in four ways to obtain relief for patients, targeting ingredients to where they are most needed:

1. Reduces pain of episodic flare ups by relaxing muscles of the gut
2. Reduces inflammation by protecting the lining of the gut
3. Restores the microbiome by promoting the growth of good bacteria
4. Repairs and regenerates the lining of the gut wall to protect against future flare ups

Current pharmaceutical treatments have high failure rates and severe side-effects, leading to over 50% of IBS<sup>3</sup> and IBD<sup>4</sup> patients trying complementary and alternative medicines (CAMs) in the hope of effectively managing their chronic bowel condition. As many patients and healthcare providers believe the risk benefit of CAMs to be favourable, patients are willing to invest in their health, with this market segment being significant. In 2018, expenditure on gastrointestinal supplements and OTC digestive remedies in the US alone was US\$8 billion<sup>5,6</sup>.

<sup>1</sup> Clinical Gastroenterology and Hepatology 2012; 10, 712-721.

<sup>2</sup> Crohn's and Colitis Australia.

<sup>3</sup> Grundmann O & Yoon S (2014) World J. Gastroenterol 20 (2). p.346.

<sup>4</sup> Lovell R & Ford A (2012) Clin. Gastroenterol. Hepatol. 10. p.712

<sup>5</sup> Mintel's 2018 Digestive Health U.S., July 2019.

<sup>6</sup> 2018 category insight Report: follow your gut-a global look at Digestive Health Products.

### For more information please contact:

General inquiries	
Steven Lydeamore CEO, Anatara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anatara.com	Sue MacLeman Chair, Anatara Lifesciences Ltd +61 (0) 437 211 200 smacleman@anatara.com

## About Anataro Lifesciences Ltd

Anataro Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anataro is a life sciences company with expertise in developing products for animal and human health. Anataro is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

### Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anataro Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.



## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

Anatara Lifesciences Ltd (ASX: ANR)

**ABN**

41 145 239 872

**Quarter ended ("current quarter")**

30 June 2020

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (12 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	(184)	(995)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(357)	(1,731)
(f) administration and corporate costs	(201)	(1142)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	6	94
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	78	925
1.8 Other (GST refunded)	32	141
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(626)</b>	<b>(2,708)</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(1)	(4)
(d) investments	-	(1,500)
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	1	1
	(d) investments	500	5,550
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>500</b>	<b>4,047</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>-</b>	<b>-</b>

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	2,809	1,360
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(626)	(2,708)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	500	4,047

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-
4.5	Effect of movement in exchange rates on cash held	(1)	(17)
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>2,682</b>	<b>2,682</b>

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,182	1,809
5.2	Call deposits	1,500	1,000
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>2,682</b>	<b>2,809</b>

**6. Payments to related parties of the entity and their associates**

- 6.1 Aggregate amount of payments to related parties and their associates included in item 1
- 6.2 Aggregate amount of payments to related parties and their associates included in item 2

**Current quarter  
\$A'000**

86

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

Item 6.1 Reflects amounts paid to directors including director's fees and superannuation (excluding reimbursements).

**7. Financing facilities**

*Note: the term "facility" includes all forms of financing arrangements available to the entity.*

*Add notes as necessary for an understanding of the sources of finance available to the entity.*

	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 <b>Total financing facilities</b>	-	-

7.5 **Unused financing facilities available at quarter end** -

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

N/A

<b>8. Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1 Net cash from / (used in) operating activities (Item 1.9)	(626)
8.2 Cash and cash equivalents at quarter end (Item 4.6)	2,682
8.3 Unused finance facilities available at quarter end (Item 7.5)	-
8.4 Total available funding (Item 8.2 + Item 8.3)	2,682
8.5 <b>Estimated quarters of funding available (Item 8.4 divided by Item 8.1)</b>	4

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 29th July 2020



Steven Lydeamore, Chief Executive Officer

Authorised by: The Board of Anantara Lifesciences Ltd in compliance with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations.

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.